Fig. 1.

Immunogenicity of SEREX-defined antigens and outcome in patients with pancreatic adenocarcinoma. a The immunogenicity of SEREX-identified MIA, IFITM3 or PNLIPRP2 was determined by ELISA-based detection of circulating autoantibodies serving as a read-out of the humoral immune response. The frequency of antigen-specific and cumulative antibody seropositivity of donors and patients with pancreatic cancer was calculated and related to the survival time. b Kaplan–Meier analysis showed a better outcome trend for the patients carrying autoantibodies against the SEREX-identified antigens